Ferdinando Nicoletti
Ferdinando Nicoletti
University of Catania, Biomedical and Biotechnological Sciences
Verified email at unict.it - Homepage
TitleCited byYear
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging
LS Steelman, WH Chappell, SL Abrams, CR Kempf, J Long, P Laidler, ...
Aging (Albany NY) 3 (3), 192, 2011
4792011
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health
WH Chappell, LS Steelman, JM Long, RC Kempf, SL Abrams, RA Franklin, ...
Oncotarget 2 (3), 135, 2011
4492011
ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis
Y Al-Abed, D Dabideen, B Aljabari, A Valster, D Messmer, M Ochani, ...
Journal of Biological Chemistry 280 (44), 36541-36544, 2005
2872005
GSK-3 as potential target for therapeutic intervention in cancer
JA McCubrey, LS Steelman, FE Bertrand, NM Davis, M Sokolosky, ...
Oncotarget 5 (10), 2881, 2014
2612014
Vitamin D3: a helpful immuno‐modulator
M Di Rosa, M Malaguarnera, F Nicoletti, L Malaguarnera
Immunology 134 (2), 123-139, 2011
2542011
Molecular mechanisms involved in NAFLD progression
M Malaguarnera, M Di Rosa, F Nicoletti, L Malaguarnera
Journal of molecular medicine 87 (7), 679, 2009
2472009
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance
JA McCubrey, LS Steelman, WH Chappell, SL Abrams, RA Franklin, ...
Oncotarget 3 (10), 1068, 2012
2412012
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response
JA McCubrey, LS Steelman, WH Chappell, SL Abrams, G Montalto, ...
Oncotarget 3 (9), 954, 2012
2332012
Biphasic effect of interferon‐γ in murine collagen‐induced arthritis
MC Boissier, G Chiocchia, N Bessis, J Hajnal, G Garotta, F Nicoletti, ...
European journal of immunology 25 (5), 1184-1190, 1995
2201995
The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients
AM Martelli, C Evangelisti, F Chiarini, JA McCubrey
Oncotarget 1 (2), 89, 2010
2162010
Targeting the leukemic stem cell: the Holy Grail of leukemia therapy
N Misaghian, G Ligresti, LS Steelman, FE Bertrand, J Bäsecke, M Libra, ...
Leukemia 23 (1), 25, 2009
2022009
Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy
LS Steelman, RA Franklin, SL Abrams, W Chappell, CR Kempf, J Bäsecke, ...
Leukemia 25 (7), 1080, 2011
1992011
Endothelial activation by aPL: a potential pathogenetic mechanism for the clinical manifestations of the syndrome
PL Meroni, E Raschi, M Camera, C Testoni, F Nicoletti, A Tincani, ...
Journal of autoimmunity 15 (2), 237-240, 2000
1822000
Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention
NM Davis, M Sokolosky, K Stadelman, SL Abrams, M Libra, S Candido, ...
Oncotarget 5 (13), 4603, 2014
1712014
Serum concentrations of the interferon-γ-inducible chemokine IP-10/CXCL10 are augmented in both newly diagnosed type I diabetes mellitus patients and subjects at risk of …
F Nicoletti, I Conget, M Di Mauro, R Di Marco, MC Mazzarino, K Bendtzen, ...
Diabetologia 45 (8), 1107-1110, 2002
1592002
Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway
AM Martelli, C Evangelisti, W Chappell, SL Abrams, J Bäsecke, F Stivala, ...
Leukemia 25 (7), 1064, 2011
1542011
PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches
G Ligresti, L Militello, LS Steelman, A Cavallaro, F Basile, F Nicoletti, ...
Cell cycle 8 (9), 1352-1358, 2009
1442009
Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention
JA McCubrey, LS Steelman, FE Bertrand, NM Davis, SL Abrams, ...
Leukemia 28 (1), 15, 2014
1402014
Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways
JA McCubrey, LS Steelman, CR Kempf, WH Chappell, SL Abrams, ...
Journal of cellular physiology 226 (11), 2762-2781, 2011
1392011
Akt as a therapeutic target in cancer
LS Steelman, KM Stadelman, WH Chappell, S Horn, J Bäsecke, ...
Expert opinion on therapeutic targets 12 (9), 1139-1165, 2008
1342008
The system can't perform the operation now. Try again later.
Articles 1–20